robot doctor.jpg

Dr. Robot? Chinese robot is the first to pass a medical exam

In China, a robot has passed the written test of their national medical licensing exam, an essential entrance exam for doctors, making it the first robot in the world to pass such an exam. While many people will worry about how this will affect jobs in the future, the initial impact should be extremely positive in assisting doctors to analyze data faster and more comprehensively than ever before. This could also help to reduce healthcare cost while improving outcomes.

Its developer iFlytek Co Ltd, a leading Chinese artificial intelligence company, said that the robot scored 456 points, comfortably passing the required mark by 96 points. The robot can automatically capture and analyze patient information and make initial diagnosis. The company said that the robot will be used to assist doctors to improve efficiency in future treatments.

Liu Qingfeng, chairman of iFlytek, said, "We will officially launch the robot in March 2018. It is not meant to replace doctors. Instead, it is to promote better people-machine cooperation so as to boost efficiency."

The company is conducting a pilot project with the Anhui Provincial Hospital to see how the AI robot can assist doctors in real medical cases.

"General practitioners are in severe shortage in China's rural areas. We hope AI can help more people access quality medical resources."

JP Morgan bullish on China

JP Morgan's chairman and CEO for Asia Pacific, Nicolas Aguzin, is extremely bullish on the prospects of China and their innovation in technology is one of the biggest reasons. Aguzin expects China to have at least a quarter of the world's top 500 companies, and account for 20 percent of GDP within a decade from its current World Bank estimate of more than 14 percent.

“There is a lot of creativity and innovation in China, a lot of new businesses emerging every day,” Aguzin added. “A lot have innovative concepts that have not yet been seen in other parts of the world, such as in insurtech.”

He said his banks’ areas of focus will be the technology, health care and consumer sectors, particularly Chinese companies related to artificial intelligence, autonomous tech, and internet banking.

Are you excited by the news of Dr. Robot?

 china tip sheet

Share This Story, Choose Your Platform!

About the Author: Chris Wang

Chris Wang

IMPORTANT DISCLOSURE INFORMATION 

Please remember that past performance may not be indicative of future results.  Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product (including the investments and/or investment strategies recommended or undertaken by Runnymede Capital Management, Inc.-"Runnymede"), or any non-investment related content, made reference to directly or indirectly in this blog will be profitable, equal any corresponding indicated historical performance level(s), be suitable for your portfolio or individual situation, or prove successful.  Due to various factors, including changing market conditions and/or applicable laws, the content may no longer be reflective of current opinions or positions.  Moreover, you should not assume that any discussion or information contained in this blog serves as the receipt of, or as a substitute for, personalized investment advice from Runnymede.  Please remember that if you are a Runnymede client, it remains your responsibility to advise Runnymede, in writing, if there are any changes in your personal/financial situation or investment objectives for the purpose of reviewing/evaluating/revising our previous recommendations and/or services, or if you would like to impose, add, or to modify any reasonable restrictions to our investment advisory services. To the extent that a reader has any questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional advisor of his/her choosing. Runnymede is neither a law firm nor a certified public accounting firm and no portion of the blog content should be construed as legal or accounting advice. A copy of the Runnymede's current written disclosure Brochure discussing our advisory services and fees is available for review upon request. Please Note: Runnymede does not make any representations or warranties as to the accuracy, timeliness, suitability, completeness, or relevance of any information prepared by any unaffiliated third party, whether linked to Runnymede's web site or blog or incorporated herein, and takes no responsibility for any such content. All such information is provided solely for convenience purposes only and all users thereof should be guided accordingly.